Clinical trials: Prostate Specific Antigen
Prostate Cancer (Diagnosis)
Virtual Biopsy of Prostate Cancer Using PSMA PET and AI
Prostate cancer is the most common type of cancer in Norwegian men, but many tumors are slow-growing and do not require treatment.
- Trial name
- NCT07266129
- Where
- Norway
- Volunteers
- 220 people
- Sponsor
- University Hospital of North Norway
Prostatic Neoplasms
Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient
It is a cross sectional study aimed to correlate between PSA Levels and F-18 PSMA PET/CT Scan findings and to evaluate the impact of PET/CT findings on the patient management
- Trial name
- NCT06209853
- Testing
- PSMA PET/CT
- Where
- Egypt
- Volunteers
- 59 people
- Sponsor
- Assiut University
Prostate Cancer
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003653
- Testing
- bicalutamide, buserelin, cyproterone acetate
- Where
- 29 sites in Canada
- Volunteers
- 1,386 people
- Sponsor
- NCIC Clinical Trials Group
Prostatic Neoplasms
Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer
The primary purpose of the study is to determine if a new sustained-release 45 mg (depot) formulation of leuprolide acetate will reduce serum testosterone levels to and maintain them at medically castrate levels in subjects with…
- Trial name
- NCT00056654
- Testing
- Leuprolide acetate
- Where
- 55 sites in United States
- Volunteers
- 164 people
- Sponsor
- Abbott
Prostate Cancer
Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy
Clinical data are being used to build a mathematical model to describe the clinical results of radiotherapy for prostate cancer.
- Trial name
- NCT00126815
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- AHS Cancer Control Alberta
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen
RATIONALE: Eating a diet high in soy foods may lower the risk of some types of cancer. Isoflavones are compounds found in soy food that may prevent cancer.
- Trial name
- NCT01682941
- Testing
- Arm I Soy Bread, Arm II Soy-Almond Bread
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Prostate Cancer
Effects of GCP on Prostate Cancer.
Genistein Combined Polysaccharide (GCP) is derived from adding soy powder to shiitake mushrooms. This concentrated mixture is currently being sold in Japan and the United States and is thought to possibly contain properties that…
- Trial name
- NCT00269555
- Testing
- Genistein Combined Polysaccharide (GCP)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of California, Davis
Prostatic Neoplasms, Prostate-Specific Antigen
Prognostic Study of Prostate Cancer Via Dynamic Change of PSA in Peritoneal Drainage Fluid After Radical Prostatectomy
This study investigates the prognostic value of dynamic changes in Prostate-Specific Antigen (PSA) levels found in the peritoneal drainage fluid after radical prostatectomy.
- Trial name
- NCT06608225
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Prostate Cancer
TKI258 in Castrate Resistant Prostate Cancer
The goal of this clinical research study is to learn if a decrease in the levels of prostate specific antigen (PSA) may be linked with the status of prostate cancer that has spread to the bones.
- Trial name
- NCT00831792
- Testing
- TK1258
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Pathological Positivity Rate in Prostate Cancer Patients with PI-RADS 4 and First Negative Biopsy
The purpose of this prospective, single-center, single-arm trial was to evaluate the pathologic type of re-treatment based on a clear PI-RADS score of ≥4 with a first negative prostate biopsy, belonging to the high-risk group of…
- Trial name
- NCT06677775
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Anhui Provincial Hospital
Prostatic Neoplasm
A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
One current hypothesis as to what limits duration of initial hormone response is the rapid emergence of hormone resistant prostate carcinoma cells.
- Trial name
- NCT00001266
- Testing
- Suramin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Evidence Based Medicine
A Cluster Package Intervention to Promote an Evidence-based Use of PSA-tests in General Practice
It is widely acknowledged that prostate specific antigen (PSA) testing can lead to false-positives, overdiagnosis and overtreatment of prostate cancer.
- Conditions
- Prostate Cancer, Evidence Based Medicine, Prostate Specific Antigen
- Trial name
- NCT06748456
- Testing
- Podcast, Cluster meeting, Hand-out material 1
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- University of Copenhagen
Prostate Cancer
PROFIT - Prostate Fractionated Irradiation Trial
This trial is designed to determine whether an 8-week course of escalated dose conformal radiation can be compressed safely, and with similar efficacy into a 4-week course.
- Trial name
- NCT00304759
- Testing
- 7800 cGy/39 fractions in 8 weeks, 6000 cGy/20 fractions in 4 weeks
- Where
- 25 sites in Australia, Canada and 1 more
- Volunteers
- 1,204 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Prostate Cancer
Robotic-arm Assisted Ga-68 PSMA PET/CT Guided Transgluteal Prostate Biopsy
Gallium-68 prostate-specific-membrane-antigen (Ga-68 PSMA) PET/CT is being used in Prostate cancer imaging. In the present study, we aimed to evaluate the efficacy and safety of robotic arm-assisted Ga-68 PSMA PET/CT-guided…
- Trial name
- NCT05022576
- Testing
- Robotic arm assisted PSMA PET/CT guided prostate biopsy
- Where
- India
- Volunteers
- 78 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Prostate Cancer
Does End-fire Technique Increase Detection Rate of Prostate Cancer at First Re-biopsy Compared to Side-fire Technique?
Prostate cancer is the most common cancer among men in Sweden. During investigation of suspected cancer transrectal ultrasound with needle biopsies from prostate leeds to diagnosis.
- Trial name
- NCT02761135
- Where
- Sweden
- Volunteers
- 364 people
- Sponsor
- Kronoberg County Council
Prostate Cancer
Active Surveillance in Prostate Cancer
The goal of this clinical research study is to find out if men who have a type of prostate cancer that has been classified as "low risk" can safely not be treated for the disease.
- Trial name
- NCT00490763
- Testing
- Survey
- Where
- United States
- Volunteers
- 1,139 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Shorter Radiation Schedule for the Treatment of Prostate Cancer
To improve the management of patients with early stage prostate cancer.
- Trial name
- NCT00201916
- Testing
- 5250 cGy/20 fractions over 28 days, 6600 cGy/33 fractions over 45 days
- Where
- 16 sites in Canada
- Volunteers
- 936 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Prostate Cancer
Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1
To qualitatively determine the imaging performance of PET-CT imaging subsystem of the RefleXion X1 System Device in patients undergoing standard-of-care (SOC) [68Ga]-PSMA-11 PET-CT using Illuccix on the same day.
- Trial name
- NCT06353321
- Testing
- PET-CT imaging subsystem of the RefleXion X1 System Device
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer
Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer
This is a multi-center, open-label, dose finding study of CV787 adenovirus in patients with hormone refractory metastatic prostate cancer.
- Trial name
- NCT00116155
- Testing
- CV787 (CG7870)
- Sponsor
- Cell Genesys
Decision Making, Shared, Prostate-Specific Antigen
Promoting Shared-decision Making in Opportunistic Screening for Prostate Cancer
In this project, the investigators aim to evaluate the most appropriate design and implementation strategy of a decision-aid to promote shared-decision making in prostate cancer screening.
- Conditions
- Decision Making, Shared, Prostate-Specific Antigen, Prostate Cancer
- Trial name
- PROSHADE (NCT05187949)
- Testing
- Mixed-method approach
- Volunteers
- 1,781 people, healthy volunteers welcome
- Sponsor
- Universidad Miguel Hernandez de Elche